NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Barnes & Noble
(BKS - Get Report)
downgraded at BofA/Merrill to Underperform from Neutral on uncertainty surrounding the company's digital initiatives and a deteriorating balance sheet. Price target reduced to $13 from $15.
(DHR - Get Report)
rated new Buy at Citigroup. $47 price target. Recent acquisitions boost the company's growth profile.
(EMR - Get Report)
rated new Hold at Citigroup. $53 price target. Company appears to have overpaid for a recent acquisition and is at risk if growth in China slows down.
(GE - Get Report)
rated new Buy at Citigroup. $19 price target. Company should be able to rescue its earnings growth.
(GSK - Get Report)
downgraded at Jefferies from Buy to Hold. Risk is increasing that Avandia could be removed from the market.
(HON - Get Report)
rated new Hold at Citigroup. $45 price target. Company continues to face headwinds in aerospace and commercial construction.
rated new Hold at Citigroup. Valuation call, based on a $90 price target.
downgraded at Goldman from Buy to Neutral. $7.85 price target. Tablet demand is weighing heavily on the PC market. Estimates also lowered.
downgraded at Goldman from Neutral to Sell. $16 price target. Valuation call. Stock has a 5% dividend yield, but also faces margin compression.
upgraded at UBS from Neutral to Buy. $33.50 price target. Stock has pulled back 25% since earnings, and the company should deliver solid fourth-quarter growth.
rated new Buy at Janney. $30 price target. Company is leveraged to continued growth in the water sector.
(NOK - Get Report)
downgraded at Citigroup from Hold to Sell. $7.93 price target. Company should not trade at a premium to its peers.
initiated at Barclays with an Overweight rating and $18 price target. Above industry sales growth combined with solid margin expansion drives positive view.
initiated at Credit Suisse with an Outperform rating and $16 price target. Key drivers: margin expansion and financial deleveraging.
upgraded at BofA/Merrill to Neutral from Underperform on healthy volume trends. Price target jumped to $59 from $52.
upgraded at UBS from Neutral to Buy. $42 price target. High specification jackup dayrates are moving up ahead of expectations.
downgraded at BofA/Merrill to Neutral from Buy, valuation call. No change to $45 price target.